Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish global pharmaceutical firm Lundbeck through its US subsidiary has launched Northera (droxidopa) capsules for the treatment of neurogenic orthostatic hypotension (NOH).
Subscribe to our email newsletter
The US Food and Drug Administration (FDA) has recently approved Northera to treat NOH, a disorder caused by an underlying neurologic disease.
Currently, the norepinephrine pro-drug Northera is available across the US through a specialty pharmacy.
The drug is indicated to treat orthostatic dizziness, lightheadedness in adult patients with symptomatic NOH caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Lundbeck US president Staffan Schüberg said for people living with symptomatic NOH, the availability of Northera may provide a new treatment option to discuss with their healthcare provider.
"As a company with a long-standing and proven track record of working closely with smaller patient populations facing considerable unmet medical needs, we are passionate about delivering this needed therapy to patients and their families," Schüberg said.
The most common adverse events in patients treated with Northera were headache, dizziness, nausea, and hypertension.